Fludarabine for Treatment of Adult Acute Myelogenous Leukemia

References

• LePage G. A., Khaliq A., Gottleib J. A. Studies of 9–β-D-arabinofuranosyladenine in man. Drug Metab. Dis-pos. 1973; 1: 756–759
   PubMed Web of Science ®Google Scholar
• Montgomery J. A., Clayton S. D., Shortnacy A. T. An improved procedure for the preparation of 9–β-D-wabinofuranosyl-2–fluoroadenine. J. Heterocyclic. Chem. 1979; 16: 157–160
   Web of Science ®Google Scholar
• Brockman R. W., Schabel F. M., Jr., Montgomery J. A. Biologic activity of 9–β-D-arabinofuranosyl-2–fluo-roadenine, a metabolically stable analog of 9–β-D-arabino-furanosyladenine. Biochem. Pharmacol. 1977; 26: 2193–2196
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Chun H. G., Leyland-Jones B. R., Caryk S. M., et al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep. 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Spriggs D. R., Stopa E., Mayer R. J., et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Danhauser L., Plunkett W., Keating M., et al. 94–D-arabinofuranosyl-2–fluoroadenine 5′-monophosphate phar-macokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. 1986; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Danhauser L., Plunkett W., Liliemark J., et al. Comparison between the plasma and intracellular pharmacology of 1–β-D-arabinofuranosylcytosine and 9–P-D-arabino-furanosyl-2–fluoroadenine 5′-monophosphate in patients with relapsed leukemia. Leukemia 1987; 1: 638–643
   PubMed Web of Science ®Google Scholar
• Kemena A., Gandhi V., Shewach D. S., et al. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother. Pharmacol. 1992; 31: 193–199
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., et al. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol. 1988; 30: 461–466
   PubMedGoogle Scholar
• Keating M. J., Kantarjian H., Talpaz M., et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Keating M. J., O'Brien S., Kantarjian H., et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
   PubMed Web of Science ®Google Scholar
• Grever M. R., Coltman C. A., Files J. C., et al. Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 1986; 68: 223a
   Google Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 457–459
   PubMedGoogle Scholar
• Puccio C. A., Mittelman A., Lichtman S. M., et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 1562–1515
   PubMed Web of Science ®Google Scholar
• Kemena A., O-Brien S., Kantarjian H., et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leukemia and Lymphoma 1993; 10: 187–193
   PubMed Web of Science ®Google Scholar
• Robertson L. E., O-Brien S., Koller C., et al. Fludarabine in chronic lymphocytic leukemia: A phase II evaluation of a three day schedule. J. Clin. Oncol. 1993, submitted
   Google Scholar
• Kemena A., Keating M. J., Plunkett W. Plasma and cellular bioavailability of oral fludarabine. Blood 1991; 78: 52a
   Google Scholar
• Gandhi V., Kemena A., Keating M. J., et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia and Lymphoma 1993; 10: 49–52
   PubMed Web of Science ®Google Scholar
• Huang P., Plunkett W. Action of 9–P-D-arabi-nofuranosyl-2–fluoroadenine on RNA metabolism. Mol. Pharmacol. 1991; 39: 449–455
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2–chloro-2′-deoxyadenosine and 9–β-D-arabinosyl-2–fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Tseng WC., Derse D., Cheng YC. In vitro biological activity of 9–β-D-arabinofuranosyl-2–fluoroadenine and the biochemical actions of its triphosphate on DNA poly-merases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. 1982; 21: 474–417
   PubMed Web of Science ®Google Scholar
• White E. L., Shaddix S. C., Brockman R. W. Comparison of the actions of 9–β-D-arabinofuranosyl-2–fluo-roadenine and 9–β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 1982; 42: 2260–2264
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Cell cycle specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother. Pharmacol. 1992; 31: 11–17
   PubMed Web of Science ®Google Scholar
• Catapano C. V., Chandler K. B., Fernandes D. J. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine phosphate. Cancer Res. 1991; 51: 1829–1835
   PubMed Web of Science ®Google Scholar
• Catapano C. V., Perrino F. W., Fernandes D. J. Primer RNA chain termination induced by 9–β-D-arabinofur-anosyl-2–fluoroadenine 5′-triphosphate: A mechanism of DNA synthesis inhibition. J. Biol. Chem. 1993; 268: 7179–7185
   PubMed Web of Science ®Google Scholar
• Parker W. B., Bapat A. R., Shen JX., et al. Interaction of 2–halogenated dATP analogs (F, C1, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol. 1988; 34: 485–491
   PubMed Web of Science ®Google Scholar
• Huang P., Chubb S., Plunkett W. Termination of DNA synthesis by 9–β-D-arabinofuranosyl-2–fluoroaden-ine. A mechanism for cytotoxicity. J. Biol. Chem. 1990; 265: 16617–16625
   PubMed Web of Science ®Google Scholar
• Kamiya K., Huang P., Plunkett W. Excision of incorporated fludarabine from DNA by human DNA poly-merase. Proc. Am. Assoc. Cancer Res. 1993; 34: 349
   Google Scholar
• Yang SW., Huang P., Plunkett W., et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9–β-D-arabinofuranosyl-2–fluoroadenine triphosphate. J. Biol. Chem. 1992; 267: 2345–2349
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988; 48: 329–334
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J., Adams T. M., et al. Saturation of 1–β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1–β-D-arabinosyl-cytosine therapy. Cancer Res. 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J., Estey E., et al. Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin. Oncol 1987; 14(Suppl. 1)159–166
   PubMedGoogle Scholar
• Gandhi V., Estey E., Keating M. J., et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leukemia and Lymphoma 1993; 10(Suppl.)109–114
   PubMedGoogle Scholar
• Gandhi V., Estey E., Keating M. J., et al. Fludarabine potentiates the metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Gandhi V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia and Lymphoma 1993; 4: 343–350
   Web of Science ®Google Scholar
• Estey E., Gandhi V., Keating M. J., et al. G-CSF potentiates clinical and pharmacokinetic response to fludarabine and ara-C in AML and MDS. Proc. Am. Soc. Clin. Oncol. 1993; 12: 301
   Google Scholar
• Gandhi V., Chapman A., Huang P., et al. Molecular mechanism of synergy of fludarabine and arabinosylcytosine therapy for acute myelogenous leukemia. Proc. Am. Assoc. Cancer Res. 1993; 34: 220
   Google Scholar
• Feldman E., Gandhi V., Plunkett W., et al. Sequential administration of fludarabine, ara-C, and mitoxan-trone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia. Blood 1992; 80(Suppl. l)208a
   Google Scholar
• Robertson L. E., Kantarjian H., O'Brien S., et al. Cisplatin, fludarabine, and ara-C: A regimen for advanced fludarabine refractory chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol. 1993; 12: 308
   Google Scholar
• Yang L. Y., Li L., Trujillo J. M., et al. Fludarabine synergizes cisplatin cytotoxicity in LoVo haman colon carcinoma cells by inhibiting repair of cisplatin-induced DNA damage. Proc. Am. Assoc. Cancer Res. 1993; 34: 347
   Google Scholar
• Gregoire V., Hunter N., Milas L., et al. Enhancement of radiation response by fludarabine in murine tumor models. Proc. Am. Assoc. Cancer Res. 1992; 33: 85
   Google Scholar
• Tafuri A., Andreeff M. Kinetic rationale for cy-tokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1991; 4: 826–834
   Web of Science ®Google Scholar
• Koistinen P., Wang C., Curtis J. E., et al. Granu-locyte-macrophage colony stimulating factor and interleuken-3 protect leukemic blast cells from ara-C toxicity. Leukemia 1991; 5: 789–795
   PubMed Web of Science ®Google Scholar